Maron BJ, Rowin EJ, Udelson JE, Maron MS (2018) Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. JACC Heart Fail 6:353–363. https://doi.org/10.1016/j.jchf.2017.09.011

Article  PubMed  Google Scholar 

Hodges K, Rivas CG, Aguilera J, Borden R, Alashi A, Blackstone EH, Desai MY, Smedira NG (2019) Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. J Thorac Cardiovasc Surg 157:2289–2299. https://doi.org/10.1016/j.jtcvs.2018.11.148

Article  PubMed  Google Scholar 

Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396:759–769. https://doi.org/10.1016/S0140-6736(20)31792-X

Article  PubMed  CAS  Google Scholar 

Owens AT, Desai M, Wheeler MT, Rodonski A, Merali S, Sehnert AJ, Saberi S (2024) Mavacamten for obstructive hypertrophic cardiomyopathy: rationale for clinically guided dose titration to optimize individual response. J Am Heart Assoc 13:e033767. https://doi.org/10.1161/JAHA.124.033767

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jiang S, Sardesai K, Yousaf A, Norgard N, ASIF T (2024) Abstract 4136023: eligibility and barriers of mavacamten therapy in patients with hypertrophic cardiomyopathy: a retrospective analysis. Circulation 150. https://doi.org/10.1161/circ.150.suppl_1.4136023

Veselka J, Jensen M, Liebregts M, Cooper RM, Januska J, Kashtanov M, Dabrowski M, Hansen PR, Seggewiss H, Hansvenclova E, Bundgaard H, ten Berg J, Hilton Stables R, Faber L (2020) Alcohol septal ablation in patients with severe septal hypertrophy. Heart 106:462–466. https://doi.org/10.1136/heartjnl-2019-315422

Article  PubMed  Google Scholar 

Scholtz S, Rudolph V, Reil J-C (2023) Alcohol septal ablation or mavacamten for obstructive hypertrophic cardiomyopathy. J Clin Med. https://doi.org/10.3390/jcm12206628

Article  PubMed  PubMed Central  Google Scholar 

Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR (2010) Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol 55:823–834. https://doi.org/10.1016/j.jacc.2009.09.047

Article  PubMed  Google Scholar 

Lawin D, Stellbrink C, Stellbrink E, Buck B, Poudel MR, Tego A, Marx K, Lawrenz T (2023) Alcohol septal ablation in patients aged 75 years or older with hypertrophic obstructive cardiomyopathy. Heart 109:1778–1784. https://doi.org/10.1136/heartjnl-2023-322659

Article  PubMed  Google Scholar 

Lawin D, Lawrenz T, Radke K, Stellbrink C (2022) Safety and efficacy of alcohol septal ablation in adolescents and young adults with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 111:207–217. https://doi.org/10.1007/s00392-021-01960-6

Article  PubMed  CAS  Google Scholar 

El-Jack SS, Nasif M, Blake JW, Dixon SR, Grines CL, O’Neill WW (2007) Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation. J Interv Cardiol 20:73–76. https://doi.org/10.1111/j.1540-8183.2007.00220.x

Article  PubMed  Google Scholar 

Karimianpour A, Heizer J, Leaphart D, Rier JD, Shaji S, Ramakrishnan V, Nielsen CD, Fernandes VL, Gold MR (2021) Predicting complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy using a risk stratification model and clinical tool. Catheter Cardiovasc Interv 98:393–400. https://doi.org/10.1002/ccd.29478

Article  PubMed  Google Scholar 

Veselka J, Duchonová R, Procházková S, Pálenícková J, Sorajja P, Tesar D (2005) Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 95:675–678. https://doi.org/10.1016/j.amjcard.2004.10.050

Article  PubMed  CAS  Google Scholar 

Chang SM, Sekandarzad MW, Jiang S, Nagueh S, Spencer W, Lakkis N (2003) Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy. Am Heart J 146:1112–1114. https://doi.org/10.1016/S0002-8703(03)00504-0

Article  PubMed  Google Scholar 

Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, Gleichmann U, Horstkotte D (2003) Vorhersage des Risikos permanenter atrioventrikulärer Uberleitungsstörungen nach perkutaner Septumablation bei Patienten mit hypertropher obstruktiver Kardiomyopathie. Z Kardiol 92:39–47. https://doi.org/10.1007/s00392-003-0878-7

Article  PubMed  CAS  Google Scholar 

Ghodsi S, Masoudkabir F, Hosseini Z, Davarpasand T, Yavari N, Mohebi M, Talasaz AH, Jalali A, Ahmadi-Tafti SH, Bagheri J, Hasanzadeh H (2022) Steroid use for recovery of advanced atrioVentricular block immediately after VALvular surgery (SURVIVAL): a preliminary randomized clinical trial. J Cardiovasc Electrophysiol 33:575–585. https://doi.org/10.1111/jce.15378

Article  PubMed  Google Scholar 

Yodogawa K, Seino Y, Shiomura R, Takahashi K, Tsuboi I, Uetake S, Hayashi H, Horie T, Iwasaki Y-K, Hayashi M, Miyauchi Y, Shimizu W (2013) Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J Cardiol 62:320–325. https://doi.org/10.1016/j.jjcc.2013.07.007

Article  PubMed  Google Scholar 

Lazzerini PE, Acampa M, Cupelli M, Gamberucci A, Srivastava U, Nanni C, Bertolozzi I, Vanni F, Frosali A, Cantore A, Cartocci A, D’Errico A, Salvini V, Accioli R, Verrengia D, Salvadori F, Dokollari A, Maccherini M, El-Sherif N, Laghi-Pasini F, Capecchi PL, Boutjdir M (2021) Unravelling atrioventricular block risk in inflammatory diseases: systemic inflammation acutely delays atrioventricular conduction via a cytokine-mediated inhibition of connexin43 expression. J Am Heart Assoc 10:e022095. https://doi.org/10.1161/JAHA.121.022095

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chang SM, Nagueh SF, Spencer WH, Lakkis NM (2003) Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 42:296–300. https://doi.org/10.1016/s0735-1097(03)00623-5

Article  PubMed  Google Scholar 

Lawin D, Lawrenz T, Marx K, Danielsmeier NB, Poudel MR, Stellbrink C (2022) Gender disparities in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart 108:1623–1628. https://doi.org/10.1136/heartjnl-2022-320852

Article  PubMed  Google Scholar 

Lawrenz T, Lieder F, Bartelsmeier M, Leuner C, Borchert B, Meyer Zu, Vilsendorf D, Strunk-Mueller C, Reinhardt J, Feuchtl A, Stellbrink C, Kuhn H (2007) Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 49:2356–2363. https://doi.org/10.1016/j.jacc.2007.02.056

Article  PubMed  Google Scholar 

Chen AA, Palacios IF, Mela T, Yoerger DM, Picard MH, Vlahakes G, Lowry PA, Fifer MA (2006) Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 97:264–269. https://doi.org/10.1016/j.amjcard.2005.08.032

Article  PubMed  Google Scholar 

Veselka J, Liebregts M, Cooper R, Faber L, Januska J, Kashtanov M, Tesarkova KH, Hansen PR, Seggewiss H, Shloydo E, Popov K, Hansvenclova E, Bonaventura J, ten Berg J, Stables RH, Polakova E (2022) Outcomes of patients with hypertrophic obstructive cardiomyopathy and pacemaker implanted after alcohol septal ablation. JACC Cardiovasc Interv 15:1910–1917. https://doi.org/10.1016/j.jcin.2022.06.034

Article  PubMed  Google Scholar 

Baggish AL, Smith RN, Palacios I, Vlahakes GJ, Yoerger DM, Picard MH, Lowry PA, Jang I-K, Fifer MA (2006) Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart 92:1773–1778. https://doi.org/10.1136/hrt.2006.092007

Article  PubMed  PubMed Central  CAS  Google Scholar 

Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335:2–13. https://doi.org/10.1016/j.mce.2010.04.005

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier J-C, Rebsamen MC, Hsieh C-M, Chui D-S, Thomas KL, Prorock AJ, Laubach VE, Moskowitz MA, French BA, Ley K, Liao JK (2002) Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8:473–479. https://doi.org/10.1038/nm0502-473

Article  PubMed  PubMed Central  CAS  Google Scholar 

Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, de Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, van Tintelen JP, Ware JS, Kaski JP (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44:3503–3626. https://doi.org/10.1093/eurheartj/ehad194

Article  PubMed